Search Results - "Turner, Stewart A"

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease by QUARLES, L. Darryl, SHERRARD, Donald J, ADLER, Stephen, ROSANSKY, Steven J, MCCARY, Laura C, WEI LIU, TURNER, Stewart A, BUSHINSKY, David A

“…Current treatment of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia and…”
Get full text

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism by Lindberg, Jill S., Moe, Sharon M., Goodman, William G., Coburn, Jack W., Sprague, Stuart M., Liu, Wei, Blaisdell, Peter W., Brenner, Robert M., Turner, Stewart A., Martin, Kevin J.

“…The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. A need exists for a therapy that lowers…”
Get full text

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism by Peacock, Munro, Bilezikian, John P., Klassen, Preston S., Guo, Matthew D., Turner, Stewart A., Shoback, Dolores

“…Calcimimetics increase the sensitivity of parathyroid calcium-sensing receptors to extracellular calcium, thereby reducing PTH secretion. This multicenter,…”
Get full text

The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism by Shoback, Dolores M., Bilezikian, John P., Turner, Stewart A., McCary, Laura C., Guo, Matthew D., Peacock, Munro

“…Calcimimetics increase the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, reducing the secretion of PTH and the serum calcium…”
Get full text

Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl by Moe, Sharon M., Chertow, Glenn M., Coburn, Jack W., Quarles, L. Darryl, Goodman, William G., Block, Geoffrey A., DrEke, Tilman B., Cunningham, John, Sherrard, Donald J., Mccary, Laura C., Olson, Kurt A., Turner, Stewart A., Martin, Kevin J.

“…Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl. The National Kidney Foundation's Kidney Disease Outcomes Quality…”
Get full text

Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism by Block, Geoffrey A., Zeig, Steven, Sugihara, Jared, Chertow, Glenn M., Chi, Eric M., Turner, Stewart A., Bushinsky, David A.

“…Background. Adequate control of all four KDOQITM biochemical targets for chronic kidney disease, bone and mineral disorder (CKD-MBD), which include parathyroid…”
Get full text

The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism by GOODMAN, William G, HLADIK, Gerald A, TURNER, Stewart A, BLAISDELL, Peter W, GOODKIN, David A, WEI LIU, BARRI, Yousri M, COHEN, Raphael M, COBURN, Jack W

“…Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in many patients with secondary hyperparathyroidism due to end-stage renal disease,…”
Get full text

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism by Goodman, William G., Frazao, Joao M., Goodkin, David A., Turner, Stewart A., Liu, Wei, Coburn, Jack W.

“…A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. The calcimimetic agent R-568 lowers plasma…”
Get full text

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl by Martin, Kevin J., Juppner, Harald, Sherrard, Donald J., Goodman, William G., Kaplan, Mark R., Nassar, George, Campbell, Patricia, Curzi, Mario, Harytan, Chaim C., Mccary, Laura C., Guo, Matthew D., Turner, Stewart A., Bushinsky, David A.

“…First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. First-generation immunometric assays for…”
Get full text

P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENT by Lindstrom, Beatriz F., Ruckle, Jon L., Turner, Stewart A., Stauber, Kathe, Brierley, Stuart M., English, Brett A., Yacyshyn, Bruce

Get full text

P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENT by Lindstrom, Beatriz F, Ruckle, Jon L, Turner, Stewart A, Stauber, Kathe, Brierley, Stuart M, English, Brett A, Yacyshyn, Bruce

“…Abstract Introduction Abdominal pain is common and persistent in patients with IBD. Available anti-inflammatory treatments often fail to relieve pain despite…”
Get full text

Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease by Yacyshyn, Bruce, Ginsberg, Daniel C., Gilder, Kye, Walsh, Brandon, English, Brett, Turner, Stewart A., Klassen, Preston, Hanauer, Stephen B., Barish, Charles F., Higgins, Peter D.

Get full text

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis by Block, Geoffrey A, Martin, Kevin J, de Francisco, Angel L.M, Turner, Stewart A, Avram, Morrell M, Suranyi, Michael G, Hercz, Gavril, Cunningham, John, Abu-Alfa, Ali K, Messa, Piergiorgio, Coyne, Daniel W, Locatelli, Francesco, Cohen, Raphael M, Evenepoel, Pieter, Moe, Sharon M, Fournier, Albert, Braun, Johann, McCary, Laura C, Zani, Valter J, Olson, Kurt A, Drüeke, Tilman B, Goodman, William G

“…Hypercalcemia and hyperphosphatemia often complicate secondary hyperparathyroidism therapy in patients who are receiving dialysis. Unlike vitamin D and…”
Get full text

Future role of calcimimetics in end-stage renal disease by Goodman, William G, Turner, Stewart A

“…Calcimimetic agents are small organic molecules that act as allosteric activators of the calcium-sensing receptor. In parathyroid cells, they lower the…”
Get more information

Reply by Block, Geoffrey A., Zeig, Steven, Sugihara, Jared, Chertow, Glenn M., Chi, Eric M., Turner, Stewart A., Bushinsky, David A.

Get full text

Reply by Block, Geoffrey A, Zeig, Steven, Sugihara, Jared, Chertow, Glenn M, Chi, Eric M, Turner, Stewart A, Bushinsky, David A

Get full text

Reply by Block, Geoffrey A., Zeig, Steven, Sugihara, Jared, Chertow, Glenn M., Chi, Eric M., Turner, Stewart A., Bushinsky, David A.

Get full text

A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by Shpall, Elizabeth J., Wheeler, Catherine A., Turner, Stewart A., Yanovich, Saul, Brown, Randy A., Pecora, Andrew L., Shea, Thomas C., Mangan, Kenneth F., Williams, Stephanie F., LeMaistre, C. Fred, Long, Gwynn D., Jones, Roy, Davis, Mark W., Murphy-Filkins, Robyn, Parker, William R.L., Glaspy, John A.

“…This randomized study compared the number of leukaphereses required to collect an optimal target yield of 5 × 106CD34+ peripheral blood progenitor cells/kg,…”
Get full text

TECHNICAL NOTE: Achieving NKF-K-DOQI registered bone metabolism and disease treatment goals with cinacalcet HCl by Moe, Sharon M, Chertow, Glenn M, Coburn, Jack W, Quarles, LDarryl, Goodman, William G, Block, Geoffrey A, Drueeke, Tilman B, Cunningham, John, Sherrard, Donald J, McCary, Laura C, Olson, Kurt A, Turner, Stewart A, Martin, Kevin J

“…Background. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K-DOQI registered ) has established guidelines for treatment of…”
Get full text